ClinicalTrials.gg
Active, not recruitingNCT03800134AEGEANUpdated Jun 11, 2025

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

A Phase 3 interventional study of Durvalumab and Placebo in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 231 sites in 28 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 94
825 · median 74
Started
2018
with 7 others
Phase 3
17 of 94
3 open now
Primary completion
2022-11
later than 5 of 36 live
Registered
35th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 8 that started in 2018, is one of 17 in phase 3, reaches primary completion later than 5 of the 36 other live ones, and was the 35th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Resectable Non-small Cell Lung Cancer, NSCLC, Carcinoma, Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Newly diagnosed and previously untreated patients with or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease
  • World Health Organization (WHO)/ PS of 0 or 1 at enrollment
  • At least 1 lesion, not previously irradiated, that qualifies as a 1.1 Target Lesion (TL) at baseline
  • No prior exposure to immune-mediated therapy including, but not limited to, other , anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines
  • Adequate organ and marrow function
  • Confirmation of a patient's tumour PD-L1 status
  • Provision of sufficient tumour sample for evaluation and confirmation of EGFR and ALK status
  • Planned surgery must comprise lobectomy, sleeve resection, or bilobectomy

Exclusion criteria

Exclusion Criteria:

  • History of allogeneic organ transplantation
  • Active or prior documented or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome)
  • History of another primary
  • History of active primary immunodeficiency
  • Active infection including tuberculosis and C, or
  • Deemed unresectable NSCLC by multidisciplinary evaluation
  • Patients who have pre-operative radiotherapy treatment as part of their care plan
  • Patients who have or spinal cord compression
  • Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC
  • Known allergy or to any of the study drugs or
  • Existence of more than one primary tumour such as mixed small cell and NSCLC histology
  • Patients whose planned surgery at enrollment includes any of the following procedures: pneumonectomy, segmentectomies, or wedge resections
  • Patients with a documented test result confirming the presence of EGFRm or ALK translocation
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
825 participants (actual)

Study arms

  • Experimental
    Arm 1: Durvalumab with platinum-based chemotherapy

    Patients will receive durvalumab 1500 mg in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by durvalumab 1500 mg monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity The platinum-based chemotherapy will be based on tumour histology and Investigator discretion: * cisplatin with pemetrexed * carboplatin with pemetrexed * carboplatin with paclitaxel * cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)

    Drug: Durvalumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Gemcitabine · Procedure: Surgery

  • Placebo comparator
    Arm 2: Placebo with platinum-based chemotherapy

    Patients will receive placebo in combination with platinum-based chemotherapy every 3 weeks for up to 4 cycles prior to surgery, followed by placebo monotherapy every 4 weeks for up to 12 cycles after surgery unless disease is deemed unresectable, disease recurrence, or unacceptable toxicity The platinum-based chemotherapy will be based on tumour histology and Investigator discretion: * cisplatin with pemetrexed * carboplatin with pemetrexed * carboplatin with paclitaxel * cisplatin with gemcitabine (or carboplatin with gemcitabine for patients who have comorbidities or who are unable to tolerate cisplatin per the investigator's judgment)

    Other: Placebo · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Gemcitabine · Procedure: Surgery

Interventions

  • 1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period

    Also known as: MEDI4736

  • OtherPlacebo

    Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period

  • Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles

  • 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles

  • 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

  • 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

  • 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.

  • ProcedureSurgery

    Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population

    Defined as the lack of any viable tumour cells after complete evaluation in the resected lung cancer specimen and all sampled regional lymph nodes.

    Time frame: Up to approximately 15 weeks after randomization

  2. Event-Free Survival (EFS) in modified intent to treat (mITT) population

    An event is defined as documented RECIST 1.1 local or distant recurrence of lung cancer; death due to any cause; disease progression that precludes surgery or discovered upon attempting surgery that prevents completion of surgery.

    Time frame: Up to 5.5 years after first patient randomized.

Secondary outcomes

  1. Disease-free survival (DFS) in modified resected population

    Time frame: From date of randomization to approximately 5.5 years after date of resection

  2. Major Pathological Response (mPR) in modified intent to treat (mITT) population

    Time frame: Up to approximately 15 weeks after randomization

  3. Overall Survival (OS) in modified intent to treat (mITT) population

    Time frame: From date of randomization to 5.5 years after randomization

  4. Event-free survival (EFS) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population

    Time frame: From date of randomization to 5.5 years after randomization

  5. pCR in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population

    Time frame: Up to approximately 15 weeks after randomization

  6. Disease-Free Survival (DFS) in PD-L1-TC ≥1% patients in modified resected population

    Time frame: From date of randomization to 5.5 years after date of resection

  7. Major Pathological Response (mPR) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population

    Time frame: Up to approximately 15 weeks after randomization

  8. Overall Survival (OS) in PD-L1-TC ≥1% patients in modified intent to treat (mITT) population

    Time frame: From date of randomization to 5.5 years after randomization.

  9. To assess disease-related symptoms and HRQoL (EORTC QLQ-C30) in patients treated with durvalumab + chemotherapy prior to surgery followed by durvalumab post-surgery compared with placebo + chemotherapy prior to surgery followed by placebo post-surgery

    To assess disease-related symptoms, functioning, and global health status/quality of life in patients.

    Time frame: From date of screening to 6 months after last dose of IP

  10. To assess disease-related symptoms and HRQoL (EORTC QLQ-LC13) in patients treated with durvalumab + chemotherapy prior to surgery followed by durvalumab post-surgery compared with placebo + chemotherapy prior to surgery followed by placebo post-surgery

    To assess disease-related symptoms, functioning, and global health status/quality of life in patients.

    Time frame: From date of screening to 6 months after last dose of IP

  11. To assess the PK of durvalumab in blood

    To assess concentration of durvalumab in bloodstream.

    Time frame: From date of randomization to 2 months after resection

  12. Presence of ADA for durvalumab

    To evaluate the presence of antibodies following treatment with study medications.

    Time frame: From date of randomization to 3 months after last dose of IP

Other outcomes

  1. Number of participants with adverse events as assessed by CTCAE v5.0

    Time frame: From date of randomization to 3 months after last dose of IP

07

Study locations

231 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Boca Raton, Florida 33486, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Ashland, Kentucky 41101, United States
  • Research Site
    Lexington, Kentucky 40513, United States
  • Research Site
    Silver Spring, Maryland 20910, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Duluth, Minnesota 55805, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    Morristown, New Jersey 07962, United States
  • Research Site
    New York, New York 10028, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Shirley, New York 11967, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Bend, Oregon 97701, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Charleston, South Carolina 29424, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Kirkland, Washington 98034, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Buenos Aires, C1118AAT, Argentina
  • Research Site
    Caba, C1012AAR, Argentina
  • Research Site
    Caba, C1280AEB, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Pergamino, B2700CPM, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    San Salvador de Jujuy, 4600, Argentina
  • Research Site
    Viedma, R8500ACE, Argentina
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Rankweil, 6830, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, 1210, Austria
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Mons, 7000, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-090, Brazil
  • Research Site
    Campinas, 13060-904, Brazil
  • Research Site
    Curitiba, 81520-060, Brazil
  • Research Site
    Florianópolis, 88034-000, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    Sao Paulo, 01323-903, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Teresina, 64049-200, Brazil
  • Research Site
    Vitoria, 29043-260, Brazil
  • Research Site
    Plovdiv, 4004, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1797, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    Levis, Quebec G6V 3Z1, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H4J 1C5, Canada
  • Research Site
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Santiago, 7500713, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 101149, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changzhou, 213000, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guiyang, 550002, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hangzhou, 310030, China
  • Research Site
    Hangzhou, 310052, China
  • Research Site
    Hefei, 230001, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Ningbo, 315000, China
  • Research Site
    Shanghai, 200052, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shenyang, 110044, China
  • Research Site
    Shenzhen, 518035, China

Showing the first 100 of 231 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2022, 47 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 47 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Jan 11, 2019
StartActual
Dec 6, 2018
Primary completionActual
Nov 10, 2022
CompletionEst.
Sep 11, 2028
Results delay requested
Nov 8, 2023
Last update
Jun 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03800134
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 11, 2019
Start date
Dec 6, 2018
Primary completion
Nov 10, 2022
Completion
Sep 11, 2028 (estimated)
Last update
Jun 11, 2025

Study contacts

John Heymach, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion